Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

11.1%

3 terminated/withdrawn out of 27 trials

Success Rate

81.3%

-5.3% vs industry average

Late-Stage Pipeline

22%

6 trials in Phase 3/4

Results Transparency

100%

13 of 13 completed trials have results

Key Signals

6 recruiting13 with results

Enrollment Performance

Analytics

Phase 2

9(36.0%)

Phase 1

8(32.0%)

Phase 3

4(16.0%)

Phase 4

2(8.0%)

N/A

2(8.0%)

25Total

Phase 2(9)

Phase 1(8)

Phase 3(4)

Phase 4(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (27)

Showing 20 of 27 trials

NCT05183035Phase 3Recruiting

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Role: collaborator

NCT04960579Phase 1Active Not Recruiting

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Role: collaborator

NCT04102020Phase 3Completed

A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

Role: collaborator

NCT03824483Phase 2Recruiting

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Role: collaborator

NCT05430113Not ApplicableCompleted

Spinal Cord Stimulation in Spinal Muscular Atrophy

Role: collaborator

NCT06014762Phase 1Recruiting

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Role: collaborator

NCT02867384Phase 2Completed

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

Role: collaborator

NCT04855695Phase 1Recruiting

Avo In R/R And Previously Untreated MCL

Role: collaborator

NCT04446117Phase 3Active Not Recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Role: collaborator

NCT05787795Recruiting

Identifying and Characterizing Preclinical MS

Role: collaborator

NCT03041311Phase 2Completed

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Role: collaborator

NCT06300996Not ApplicableActive Not Recruiting

Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb

Role: collaborator

NCT03539744Phase 3Active Not Recruiting

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Role: collaborator

NCT06618963Phase 4Recruiting

Effect of Omalizumab in the Skin of Food Allergy Patients

Role: collaborator

NCT03272217Phase 2Terminated

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

Role: collaborator

NCT03256344Phase 1Completed

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Role: collaborator

NCT03236857Phase 1Completed

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Role: collaborator

NCT03073525Phase 2Completed

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Role: collaborator

NCT02141282Phase 2Completed

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Role: collaborator

NCT03726749Phase 4Completed

Tocilizumab Plus a Short Prednisone Taper for GCA

Role: collaborator